We develop together with internationally renowned research groups, competitive projects of the most important national and international calls, such as those of the Ministry of Health, Ministry of Education, Instituto de Salud Carlos III, Ministry of Economy and Competitiveness (MINECO), IMI, COST, or H2020, among others.
On this page, you will find those still in force and active and those already completed.
- Current
- Historical
Project sponsored by the Innovative Medicines Initiative (IMI) aimed at redesigning clinical trials by developing a favourable framework to facilitate the implementation of Remote Decentralized Clinical Trials (RDCT) in Europe.
Go to project page
FISABIO coordinó la Red Mundial de Hospitales para la Vigilancia de la Gripe, denominada «Global Influenza Hospital Surveillance Network»; (GIHSN), desde su creación por Sanofi Pasteur en 2012 hasta la temporada 2016/2017.
Currently, it is made up of hospitals in Spain (located in the Valencian Community), Canada, Mexico, Peru, Argentina, Russia, Romania, Poland, the Czech Republic, France, Tunisia, the Ivory Coast, South Africa, Kazakhstan, Serbia, Kenya, India, and China. Since the 2017/2018 season, FISABIO has participated as a partner.
VITAL – Vaccines and Infectious Diseases in the Ageing Population
A project sponsored by the Innovative Medicines Initiative (IMI), aimed at studying the disease burden of infectious diseases in those over 50 years of age. To this end, epidemiological studies will be carried out, including analyzes of the socio-economic impact, as well as a Clinical Trial to analyze the response to vaccines in this population group.
Go to project page
The PROMISE project is an initiative funded by the Innovative Medicines Initiative (IMI) to advance knowledge about Respiratory Syncytial Virus. Its main objective of the project is to better inform public health strategies and support the development and monitoring of new immunizations and therapies against this potentially deadly virus in the pediatric and elderly population. PROMISE is the continuation of RESCEU.
VAC4EU (Vaccine monitoring Collaboration for Europe) is an international association made up of research and public health units, which make up a network prepared for scientific debate and collaboratively conducting solid studies on the effect of vaccines in Europe. Aimed at citizens, healthcare professionals, public health organizations, and regulatory agencies.
As a member of this network, AIV participates in various post-authorization safety studies of the vaccines used against covid-19. Among them, the study. Covid Vaccine Monitoring, funded by the European Medicines Agency (EMA).
VAHNSI-Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses.
It is an active hospital surveillance network for the study of respiratory viruses in the Valencian Community (Spain). In turn, it feeds data to other projects such as DRIVE, GIHSN, RSV GEN or GISAID, creating a infrastructure of data sharing.
Go to project page
Financiado por programa EU4Health de la Comisión Europea, el objetivo del proyecto BUMPER es apoyar el diseño, desarrollo y promoción específica de la primera aplicación móvil europea para la prevención del cáncer.
El Código Europeo contra el Cáncer (ECAC) ha sido, durante los últimos 30 años, la herramienta preeminente para transmitir información basada en evidencia sobre los factores de riesgo de cáncer y las medidas preventivas para reducir el riesgo de cáncer. La aplicación pretende ampliar la cobertura y adopción de los mensajes del ECAC entre una población más amplia y diversa.
El AIV se encarga del paquete de trabajo de alfabetización en salud junto al Área de Cancer y Salud Pública de Fisabio y coordina la comunicación y diseminación del proyecto.
El proyecto PROTECT-EUROPE, financiado por el programa EU4Health, tiene como objetivo final aumentar las tasas de vacunación contra el virus del papiloma humano (VPH) en Europa. Para ello se va a recopilar y difundir, durante 2 años, la evidencia más reciente sobre cómo los profesionales de la salud pueden promover la vacunación contra el VPH entre padres, madres o tutores legales y jóvenes.
El AIV y el Área de Investigación en Cáncer y Salud Pública de Fisabio se encargan de la coordinación de las actividades de identificación de buenas prácticas en la comunicación individual sobre la vacunación contra el VPH entre médicos y jóvenes y sus padres/madres/tutores/as y el mapeo de estrategias sobre un paquete de vacunas para adolescentes de modo que se pueda evitar la pérdida de oportunidades de vacunación. El AIV además, participa en la comunicación y diseminación de las actividades del proyecto.
The project of the "Europe Research 2019" Dynamization Actions call State Program of R+D+i Oriented to the Society Challenges of the Ministry of Science, Innovation, and Universities for the realization of the project proposal RIA-H2020 "Addressing Vaccine Hesitancy; new strategies to increase vaccination coverage in the Member States."
VACMA – Vaccine Media Analytics
One of the greatest achievements of medical science is the development of vaccines: they are more accessible, their prices are falling, the evidence of their positive effects is increasing, and side effects have reduced. Yet, there is a growing number of people who are choosing to reject them.
This project does not focus on that visible group of opponents, but on the less visible one, where the vaccine is added to their other daily problems. The project aims to identify and understand this group.
CAP-PRI
Go to project page
Go to the project page
The RESCEU project aims to study the disease burden of Respiratory Syncytial Virus (RSV) and its economic impact. It also aims to create a sustainable and multidisciplinary European network where all the parties interested in the development of these studies are represented: the academic sector, public health, scientific societies, patient organizations, regulatory agencies and industry; and provide infrastructure to carry out future vaccines and preventive measures against RSV. The FISABIO Vaccine Area participated as an affiliate partner. The continuation of this initiative is the PROMISE project (2021).
Improving the guidelines for Informed Consent, including vulnerable populations under a gender perspective.
CONSENT is a European project financed by the EU Horizon 2020 program aimed at developing guidelines to improve the Informed Consent process in clinical trials. The project studies the implications of the gender perspective and vulnerable groups, making use of new technologies to present information.
DRIVE – Development of Robust and Innovative Vaccine Effectiveness. Increasing understanding of influenza vaccine effectiveness in Europe.
DRIVE is a public-private partnership that promotes European cooperation in influenza vaccine effectiveness studies. It seeks to establish a network of sufficient size to obtain robust, high quality, and
specific brand name for all influenza vaccines used in the EU each season.
Go to project page
VIGIRA es un ensayo clínico para estudiar los efectos de la vacuna de la gripe sobre otras infecciones respiratorias provocadas por coronavirus, bocavirus, virus respiratorio sincítico y rinovirus, entre otros.
Financiado por los Fondos de Investigación en Salud (FIS) del Instituto de Salud de Carlos III (ISCIII), estudió los efectos de la vacuna de la gripe en niños de entre 12-35 meses durante la temporada de gripe 2019–2020.
Participaron en el estudio siete centros de salud de las provincias de Valencia y Castelló.
Consulta los resultados del proyecto here.
It is expected that the results of the study will serve to develop guidelines and recommendations, both for mothers and newborns, in the context of safety during the pandemic, characterizing the course and progression of COVID-19 during pregnancy.
Vaccine monitoring and data collection are very complex, especially for pregnant women. For this reason, it is necessary to obtain quality data, which is difficult to gather in developing countries because they lack the infrastructures to do so. With this idea in mind, the Global Vaccine Safety Collaborative Initiative (GVS-MCC) was created, in which a total of 25 centers in 8 countries in Europe, Africa, and Asia participate. The study focuses on developing standardized surveillance systems that will underpin current and future vaccination schedules for pregnant women.
